Pillar oncoReveal Myeloid Sequencing Panel - A
Use
This NGS panel for Biopharma identifies somatic mutations in 58 genes frequently mutated in myeloid malignancies, including AML, MPN, MDS, and Myelofibrosis. It aids in the identification of relevant genetic mutations that can inform clinical trial inclusion and research studies, providing insight into disease mechanisms and potential therapeutic targets.
Special Instructions
This test is available for use in clinical trials or research purposes only. Stated turn-around-times are for clinical use only and subject to change based on protocol requirements. Final TATs will be specified in the biopharma study contract. Contact MPLN for expert guidance on test requirements and interpretation.
Limitations
Frozen bone marrow samples are not accepted. Extracted DNA must be isolated in a CLIA-certified lab or equivalent. Concentration and volume must be provided for all DNA samples. The test is for research use only and not for diagnostic purposes. Turnaround times are subject to change based on biopharma protocols.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5mL
Minimum Volume
3mL
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2°C to 8°C
Causes for Rejection
Improper specimen labeling; Insufficient sample volume; Clotted specimen; Specimens beyond stability
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 96 hours |
| Refrigerated | 30 days |
| Frozen | long-term |